Long term benefit of multiple sclerosis treatment: An investigation using a novel data collection technique

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1617-1624

  Conway, Devon S ^a   Miller, Deborah M ^a   O'Brien, Ralph G ^b   Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

database; glatiramer acetate; interferons; Multiple sclerosis; outcome assessment; propensity score

Indexed keywords

ANTIINFLAMMATORY AGENT;

ADULT; AMBULATORY CARE; DISABILITY; ELECTRONIC MEDICAL RECORD; EXERCISE TEST; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES; PROPENSITY SCORE; SELF REPORT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS; DATA COLLECTION; DISABILITY EVALUATION; EXERCISE TEST; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPENSITY SCORE; SELF REPORT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868008542     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512449681     Document Type: Article

References (30)

1. Katzan I, Speck M, Dopler C, et al. The Knowledge Program: an innovative, comprehensive electronic data capture system and warehouse. AMIA Annu Symp Proc. 2011. 2011 ;: 683-692
2. Gottberg K, Einarsson U, Ytterberg C, et al. Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Mult Scler. 2006 ; 12: 605-612 (Pubitemid 46940635)
3. Spitzer RL, Kroenke K, Williams JB.. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA. 1999 ; 282: 1737-1744 (Pubitemid 29533604)
4. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999 ; 52: 63-70
5. Marrie RA, Goldman M.. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007 ; 13: 1176-1182 (Pubitemid 351541422)
6. Rudick RA, Cutter G, Reingold S.. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials. Mult Scler. 2002 ; 8: 359-365
7. Polman CH, Rudick RA.. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010 ; 74: S8 - S15
8. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989 ; 112: 133-146 (Pubitemid 19056478)
9. Koch M, Uyttenboogaart M, van Harten A, et al. Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler. 2008 ; 14: 799-803
10. Tremlett H, Yinshan Z, Devonshire V.. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008 ; 14: 314-324 (Pubitemid 351676426)
11. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010 ; 74: 2004-2015
12. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 ; 7: 903-914
13. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 ; 8: 889-897
14. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998 ; 17: 2265-2281
15. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 ; 127: 757-763 (Pubitemid 27446562)
16. Dunnett C. A multiple comparisons procedure for comparing several treatments with a control. J Amer Statistical Assoc. 1955 ; 50: 1096-1121
17. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011 ; 4: 3-14
18. Cohen BA, Rivera VM.. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 ; 26: 827-838
19. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006 ; 67: 944-953 (Pubitemid 44454583)
20. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler. 2005 ; 11: 626-634 (Pubitemid 41685131)
21. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 ; 112: 1419-1428 (Pubitemid 20024212)
22. Detels R, Clark VA, Valdiviezo NL, et al. Factors associated with a rapid course of multiple sclerosis. Arch Neurol. 1982 ; 39: 337-341 (Pubitemid 12109203)
23. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry. 1995 ; 58: 300-306
24. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009 ; 66: 513-520
25. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 ; 65: 268-275
26. Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008 ; 15: 916-921
27. Confavreux C, Vukusic S, Adeleine P.. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 ; 126: 770-782 (Pubitemid 36372978)
28. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991 ; 114: 1045-1056
29. Leray E, Yaouang J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2011 ; 133 (Pt 7). 1900-1913
30. Marrie RA, Horwitz RI.. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010 ; 9: 820-828